Statin Decreases Helicobacter pylori Burden in Macrophages by Promoting Autophagy

Statins, 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase inhibitors, have been found to provide protective effects against several bacterial infectious diseases. Although the use of statins has been shown to enhance antimicrobial treated eradication and reduce -mediated inflammation, the...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Frontiers in cellular and infection microbiology 2017-01, Vol.6, p.203-203
Hauptverfasser: Liao, Wei-Chih, Huang, Mei-Zi, Wang, Michelle Lily, Lin, Chun-Jung, Lu, Tzu-Li, Lo, Horng-Ren, Pan, Yi-Jiun, Sun, Yu-Chen, Kao, Min-Chuan, Lim, Hui-Jing, Lai, Chih-Ho
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Statins, 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase inhibitors, have been found to provide protective effects against several bacterial infectious diseases. Although the use of statins has been shown to enhance antimicrobial treated eradication and reduce -mediated inflammation, the mechanisms underlying these effects remain unclear. In this study, and macrophage models were established to investigate the molecular pathways involved in statin-mediated inhibition of . -induced inflammation. Our study showed that statin treatment resulted in a dose-dependent decrease in intracellular . burden in both RAW264.7 macrophage cells and murine peritoneal exudate macrophages (PEMs). Furthermore, statin yielded enhanced early endosome maturation and subsequent activation of the autophagy pathway, which promotes lysosomal fusion resulting in degradation of sequestered bacteria, and in turn attenuates interleukin (IL)-1β production. These results indicate that statin not only reduces cellular cholesterol but also decreases the . burden in macrophages by promoting autophagy, consequently alleviating . -induced inflammation.
ISSN:2235-2988
2235-2988
DOI:10.3389/fcimb.2016.00203